皓宸医疗
(002622)
| 流通市值：22.60亿 | | | 总市值：22.60亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 134,804,640.83 | 702,897,591.79 | 526,891,688.79 | 313,635,948.22 |
| 营业收入 | 134,804,640.83 | 702,897,591.79 | 526,891,688.79 | 313,635,948.22 |
| 二、营业总成本 | 145,564,795.01 | 766,396,075.56 | 557,460,141.75 | 353,745,281.85 |
| 营业成本 | 69,227,179.55 | 389,482,401.23 | 275,451,004.26 | 178,274,250.68 |
| 税金及附加 | 485,604.56 | 2,443,714.65 | 1,642,322.95 | 1,146,432.04 |
| 销售费用 | 33,960,154.39 | 176,214,408.51 | 131,449,356.84 | 76,940,756.43 |
| 管理费用 | 30,419,067.1 | 146,007,181.93 | 106,120,338.19 | 68,770,906.66 |
| 研发费用 | 1,993,188.74 | 11,755,288.49 | 11,646,500.56 | 7,966,580.46 |
| 财务费用 | 9,479,600.67 | 40,493,080.75 | 31,150,618.95 | 20,646,355.58 |
| 其中:利息费用 | 9,273,840.58 | 40,013,214.12 | 30,282,314.67 | 20,256,561.25 |
| 其中:利息收入 | 173,599.26 | 585,214.84 | 495,510.04 | 333,837.89 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 163,372.38 | -1,076,444.51 | 2,674,802.35 | 4,349,700.1 |
| 资产处置收益 | - | 710,274.09 | 1,397,658.81 | 678,017.94 |
| 资产减值损失(新) | - | -54,379,889.42 | - | - |
| 信用减值损失(新) | 894,751.36 | 2,120,652.6 | 2,969,505.77 | 2,596,096.74 |
| 其他收益 | 2,141,846.85 | 4,543,725.19 | 3,853,792.13 | 2,835,597.49 |
| 四、营业利润 | -7,560,183.59 | -111,580,165.82 | -19,672,693.9 | -29,649,921.36 |
| 加:营业外收入 | 88,018.24 | 769,864.96 | 149,336.57 | 129,009.74 |
| 减:营业外支出 | 222,507.63 | 15,108,218.82 | 8,733,994.15 | 2,550,185.05 |
| 五、利润总额 | -7,694,672.98 | -125,918,519.68 | -28,257,351.48 | -32,071,096.67 |
| 减:所得税费用 | 953,535.9 | 4,006,754.32 | 2,767,886.59 | 2,543,284.59 |
| 六、净利润 | -8,648,208.88 | -129,925,274 | -31,025,238.07 | -34,614,381.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -8,648,208.88 | -129,925,274 | -31,025,238.07 | -34,614,381.26 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -8,340,483.51 | -119,422,451.09 | -26,409,811.01 | -23,751,065.12 |
| 少数股东损益 | -307,725.37 | -10,502,822.91 | -4,615,427.06 | -10,863,316.14 |
| 扣除非经常损益后的净利润 | -8,423,371.58 | -106,426,656.37 | -24,524,522.24 | -23,558,534.57 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | -0.14 | -0.03 | -0.03 |
| (二)稀释每股收益 | -0.01 | -0.14 | -0.03 | -0.03 |
| 八、其他综合收益 | 4,256,010.48 | -6,793,700.91 | -7,265,883.57 | -1,502,531.57 |
| 归属于母公司股东的其他综合收益 | 4,256,010.48 | -6,793,700.91 | -7,265,883.57 | -1,502,531.57 |
| 九、综合收益总额 | -4,392,198.4 | -136,718,974.91 | -38,291,121.64 | -36,116,912.83 |
| 归属于母公司股东的综合收益总额 | -4,084,473.03 | -126,216,152 | -33,675,694.58 | -25,253,596.69 |
| 归属于少数股东的综合收益总额 | -307,725.37 | -10,502,822.91 | -4,615,427.06 | -10,863,316.14 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-31 | 2025-08-29 |
| 审计意见(境内) | | 保留意见 | | |